Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018681 (headache)
 56,091 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Within the frame work of lumbar myelography, 158 patients were entered in a double-blind study in order to test a dimeric contrast medium (iotrolan) against a monomeric one (iopamidol), both of them non-ionic. A three-step scheme was applied to evaluate the X-ray pictures with respect to contrast quality. Particular attention was paid to the visibility of details, i.e. the nerve root and its course, as well as to how well it could be distinguished in the nerve root sheath. On the basis of a high level of significance (P less than 0.05), comparison of the two contrast media showed no difference in contrast quality. Sixty-nine percent of the examinations using iotrolan resulted in excellent contrast quality, whereas the corresponding very good results using iopamidol lay at 76%. Twenty-nine percent of the patients examined with iotrolan and 27% of those examined with iopamidol showed side effects. Headache occurred most frequently, followed by nausea, dizziness and neck pain. Sixty percent of the patients suffering from postmyelographic reactions reported delayed headache, which occurred most often with iotrolan rather than iopamidol. As for manifestation of other postmyelographic side effects, there were no significant differences (P less than 0.05, Fischer's test) between the two groups of contrast media.
 ...
PMID:[Iotrolan versus iopamidol. A controlled double-blind study with lumbar myelography]. 844 9

For hysterosalpingography, there were no significant differences between the non-ionic dimeric contrast medium iotrolan (300 mgI/%) and Urografin (370 mgI/%) with regard to ease of application or radiographic quality, and both agents were equally suitable. There were no significant differences between two groups of patients with regard to pain due to instrumentation, pain at the time of injection and pain up to 2 h after the procedure. There was a significant difference (p = 0.04) between the two groups with respect to delayed pain, when iotrolan was associated with a lower incidence and decreased severity of delayed pain. There were no differences in the incidence of nausea, vomiting, headache and syncope. No allergic phenomena were seen in either group.
 ...
PMID:A comparison between iotrolan, a non-ionic dimer, and a hyperosmolar contrast medium, Urografin, in hysterosalpingography. 187 59

The objective of the trial was to compare the safety and efficacy of the non-ionic, dimeric, isotonic contrast medium iodixanol (Visipaque 270 and 320 mgI/ml) with those of iotrolan (Isovist 300 mgI/ml) in myelography. After lumbar or cervical puncture, 315 patients were examined in a multicentre, double-blind, randomised, comparative myelography study. Image quality, changes in vital signs, immediate and delayed adverse events were registered. There was a tendency for better images with iodixanol 320 than with iodixanol 270 and iotrolan 300, but the overall quality was good or excellent with all products. The frequency of patients reporting adverse events and headache varied much across centres, but there was no statistically significant difference between the contrast media. The incidence of events was higher after lumbar puncture than after cervical puncture, in women rather than in men, and after puncture with a 22-gauge (G) bevel-tipped needle compared with a 24 G Sprotte needle. The frequency of headache did not correlate with the absence of pathology. The higher iodine concentration in iodixanol 320 could be an advantage for film quality. When compared with iotrolan 300, iodixanol 320 and 270 give similar incidences of adverse events, including headache.
 ...
PMID:Comparison in myelography between iodixanol 270 and 320 mgI/ml and iotrolan 300 mgI/ml: a multicentre, randomised, parallel-group, double-blind, phase III trial. 1187 Apr 88